Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

(2015) Lieke H J Simkens et al.   LANCET

Impact of Metronomic UFT/Cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma

(2015) Terence C. Tang et al.   NEOPLASIA

Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo

(2015) Bastianina Canu et al.   NEOPLASIA

Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

(2014) E. Pham et al.   CLINICAL CANCER RESEARCH

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

(2014) Silvia Novello et al.   Journal of Thoracic Oncology

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials

(2014) Shaodong Hong et al.   OncoTargets and Therapy

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues

(2013) Krupa J. Patel et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Model of Postsurgical Advanced Metastatic Breast Cancer More Accurately Replicates the Clinical Efficacy of Antiangiogenic Drugs

(2013) E. Guerin et al.   CANCER RESEARCH

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

(2013) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1

(2013) Teresa Di Desidero et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial

(2013) Alfredo Carrato et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Tumor Architecture to Favor Drug Penetration: A New Weapon to Combat Chemoresistance in Pancreatic Cancer?

(2012) Man Yu et al.   CANCER CELL

Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science

(2012) Camillo Porta et al.   Expert Review of Anticancer Therapy

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

(2012) Christina Hackl et al.   GUT

Neoadjuvant therapy of renal cell carcinoma: A novel treatment option in the era of targeted therapy?

(2012) Andres J Schrader et al.   INTERNATIONAL JOURNAL OF UROLOGY

Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning?

(2012) Hope S. Rugo   JOURNAL OF CLINICAL ONCOLOGY

First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

(2012) Jonas Bergh et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment selection in metastatic renal cell carcinoma: expert consensus

(2012) Bernard Escudier et al.   Nature Reviews Clinical Oncology

Performing Cytoreductive Nephrectomy following Targeted Sunitinib Therapy for Metastatic Renal Cell Carcinoma: A Surgical Perspective

(2012) Greg L. Shaw et al.   UROLOGIA INTERNATIONALIS

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

(2011) D. Y. Heng et al.   ANNALS OF ONCOLOGY

Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor

(2011) S. Kumar et al.   CLINICAL CANCER RESEARCH

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

(2011) K. J. Gotink et al.   CLINICAL CANCER RESEARCH

Future Directions in Renal Cell Carcinoma: 2011 and Beyond

(2011) Daniel C. Cho et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)

(2010) Joaquim Bellmunt et al.   LANCET ONCOLOGY

Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

(2010) Kae Hashimoto et al.   MOLECULAR CANCER THERAPEUTICS

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma

(2009) J-J Patard et al.   BRITISH JOURNAL OF CANCER

Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2-Positive Human Breast Cancer Xenografts

(2009) G. Francia et al.   CLINICAL CANCER RESEARCH

Resistance to targeted therapy in renal-cell carcinoma

(2009) Brian I Rini et al.   LANCET ONCOLOGY

Development of a Preclinical Model of Spontaneous Human Melanoma Central Nervous System Metastasis

(2008) W. Cruz-Munoz et al.   CANCER RESEARCH